Search results
Added:
3 years ago
Heart Failure (HF) constitutes a major global health problem, evidenced by substantial morbidity and mortality, requiring enormous healthcare-related expenditure. HF is associated with high symptomatic burden, and with a relentless and progressive clinical course towards end-stage disease. A large body of epidemiological data suggests that the prognosis in HF is as poor as in advanced cancer.1…
View more
Added:
1 year ago
AHA 22 - Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sits down with PI, Dr Robert J Mentz (Duke University of Medicine, US) to discuss the findings of the TRANSFORM-HF trial (NCT03296813).
This study aimed to compare the loop diuretics furosemide and torsemide in the treatment of patients with heart failure.Over 2800 patients were enrolled in the trial and were randomized…
View more
Added:
1 year ago
Added:
2 years ago
Added:
2 years ago
Late-breaker host, Dr Harriette Van Spall (McMaster University, CA)is joined by Principal Investigator, Prof Stefan Anker (Charite Campus Virchow Clinic, DE) for an in-depth discussion on the latest data from the EMPEROR-Preserved trial presented at ESC Congress 2021.
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction evaluated the effects of…
View more
De Novo HF Versus ADCHF
Added:
3 years ago
Article
Added:
4 years ago
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events…
View more
Added:
3 years ago
Patients with heart disease in Africa commonly present with heart failure both for admission to hospital1 and in the outpatient setting.2 Recent data suggests that, in line with high income countries, heart failure with preserved ejection fraction is also becoming more common.3 Data from the 12 clinical studies performed before 2005 in eight sub-Saharan Africa (SSA) countries have shown that up…
View more
Added:
3 years ago
Heart failure with preserved ejection fraction (HFpEF) is a common disease with rapidly increasing incidence and prevalence due to demographic changes.1 Well-known risk factors, such as metabolic syndrome (arterial hypertension, diabetes, obesity and dyslipidaemia), chronic kidney disease and AF, predispose to the development of HFpEF, especially in older people.
Establishing the clinical…
View more
The Burden of Disease of HFpEF
Added:
5 months ago
Article
« First